Zura Bio Ltd

Zura Bio Ltd, trading under the ticker ZURA, is a clinical-stage biopharmaceutical company focused on immunology and inflammatory diseases that reached the public markets through a SPAC business combination. The company filed a Form 10-Q with the SEC on May 13, 2022, accession number 0001410578-22-001433, reflecting its status as a reporting public company operating in the healthcare and life sciences sector. As a post-merger entity, Zura Bio has pursued a pipeline targeting immune-mediated conditions, placing it within the broader wave of biotech companies that accessed public capital through blank-check vehicles in the early 2020s. Visit SpacDesk and sign up for full data, filings history, and deal analytics on ZURA and hundreds of other SPAC-related companies.